Safety and Efficacy ATYR1923, a Novel Immunomodulator for Pulmonary Sarcoidosis: Results of a Phase 1b/2a Randomized Placebo-Controlled Trial
Peter H. S. Sporn(Northwestern University), R.P. Baughman(University of Cincinnati), Joseph B. Barney(University of Alabama at Birmingham), Lucian T. Marts(Emory University), G. Walker(aTyr Pharma (United States)), Leeanne M. Carey(La Trobe University), S. Shukla(aTyr Pharma (United States)), M. Tabassomi, Lisa Maier(University of Tübingen), W. Ennis James(Medical University of South Carolina), Nadera Sweiss(University of Illinois Chicago), CC Hsia(The University of Texas Southwestern Medical Center), D.A. Culver(Cleveland Clinic), Shambhu Aryal(Alaska Heart and Vascular Institute)
Cited by 1
Related Papers
Thrombolysis Guided by Perfusion Imaging up to 9 Hours after Onset of Stroke
|New England Journal of Medicine|2019|1k
Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline
|American Journal of Respiratory and Critical Care Medicine|2020|1k
The WASOG Sarcoidosis Organ Assessment Instrument: An update of a previous clinical tool.
|PubMed|2014|505
Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial
|Annals of the Rheumatic Diseases|2010|503
Bioaccumulation of therapeutic drugs by human gut bacteria
|Nature|2021|313